FLDM Fluidigm

Standard BioTools to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

Standard BioTools to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

BOSTON, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026, after U.S. market close.

About Standard BioTools Inc.

Standard BioTools Inc. (Nasdaq: LAB), has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop better medicines faster. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at or connect with us on X, Facebook®, LinkedIn, and YouTube™.

Limited Use Label License and other terms may apply: .

Patent and License Information: .

©2026 Standard BioTools Inc. All rights reserved.



Standard BioTools products are provided for Research Use Only. Not for use in diagnostic procedures.

Investor Contact:



EN
10/02/2026

Underlying

FLDMFluidigm

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Fluidigm

 PRESS RELEASE
Free
FLDM FLUIDIGM

Standard BioTools Reports Fourth Quarter and Full Year 2025 Financial ...

Standard BioTools Reports Fourth Quarter and Full Year 2025 Financial Results BOSTON, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter and fiscal year ended December 31, 2025. Recent Highlights: Fourth quarter 2025 revenue from Continuing Operations of $23.8 million; Full Year 2025 revenue of $85.3 millionFully operationalized over $40 million in previously announced annualized cost savings supporting path to positive adjusted EBITDA and adjusted cash flow exiting 2026Ap...

22h / 26m 1 EN
 PRESS RELEASE
Free
FLDM FLUIDIGM

Standard BioTools to Announce Fourth Quarter and Full Year 2025 Financ...

Standard BioTools to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 BOSTON, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026, after U.S. market close. About Standard BioTools Inc. Standard BioTools Inc. (Nasdaq: LAB), has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop better medicines faster. As a leading solutions provider, the comp...

February 10, 2026 1 EN
 PRESS RELEASE
Free
FLDM FLUIDIGM

Standard BioTools Completes Sale of SomaLogic to Illumina

Standard BioTools Completes Sale of SomaLogic to Illumina Received $350 Million in upfront cash at closing; Up to $425 Million in total proceeds inclusive of near-term earnout payments Approximately $550 Million in cash & cash equivalents on balance sheet at close, excluding potential future earnouts, to fuel inorganic growth strategy  Continuing Operations on track to achieve positive adjusted EBITDA in 2026 BOSTON, Mass., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced it has completed the previously announ...

January 30, 2026 1 EN
 PRESS RELEASE
Free
FLDM FLUIDIGM

Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2...

Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2025 Revenue Preliminary, unaudited combined company revenue for the full year 2025 of approximately $185 million; Revenue from continuing operations of approximately $85 million BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools” or the “Company”) today announced preliminary and unaudited revenue results for the fourth quarter and full year 2025. Standard BioTools expects fourth quarter 2025 combined company revenue of approximately $56 million and revenue from continuin...

January 8, 2026 1 EN
Jonathan Moreland
  • Jonathan Moreland
Free Trial
RPD RAPID7 INC.
GLP Global Partners... ... (+26)

InsiderInsights.com Daily Ratings Report: December 4, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

RPD RAPID7 INC.
GLP GLOBAL PARTNERS LP
FLDM FLUIDIGM
CBRL CRACKER BARREL OLD COUNTRY STORE INC.
MSBI MIDLAND STATES BANCORP
WMG WARNER MUSIC GROUP CORP.
IIIV I3 VERTICALS
GRX THE GABELLI HEALTHCARE & WELLNESSRX TRUST
SPT SPROUT SOCIAL
BMEA INC.
PBBK BIOMEA FUSION
NRDY INC.
MAIA PB BANKSHARES
SMRT INC.
SPRU NERDY INC.
BAER MAIA BIOTECHNOLOGY INC
SGI SMARTRENT INC
GF SPRUCE POWER HOLDING CORP
AFCG WILDFIRE NEW PUBCO
KITT INC.
SOMNIGROUP INTERNATIONAL INC.
THE NEW GERMANY FUND
INC.
AFC GAMMA
INC.
NAUTICUS ROBOTICS HOLDINGS INC.
12/05/25 December 5, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch